These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Ren H; Yang BF; Rainov NG Rev Recent Clin Trials; 2007 May; 2(2):87-101. PubMed ID: 18473993 [TBL] [Abstract][Full Text] [Related]
85. A RTK-based functional RNAi screen reveals determinants of PTX-3 expression. Liu H; Qu XK; Yuan F; Zhang M; Fang WY Int J Clin Exp Pathol; 2013; 6(4):660-8. PubMed ID: 23573312 [TBL] [Abstract][Full Text] [Related]
86. Epigenetic regulation of RTK signaling. Spangle JM; Roberts TM J Mol Med (Berl); 2017 Aug; 95(8):791-798. PubMed ID: 28589435 [TBL] [Abstract][Full Text] [Related]
87. The sum is greater than the FGFR1 partner. Braun BS; Shannon K Cancer Cell; 2004 Mar; 5(3):203-4. PubMed ID: 15050910 [TBL] [Abstract][Full Text] [Related]
88. Relationships between DNA repair and RTK-mediated signaling pathways. Chabot T; Cheraud Y; Fleury F Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188495. PubMed ID: 33346130 [TBL] [Abstract][Full Text] [Related]
89. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Kashyap MK; Abdel-Rahman O Mol Cancer; 2018 Feb; 17(1):54. PubMed ID: 29455652 [TBL] [Abstract][Full Text] [Related]
90. Interactions between cholinergic and fibroblast growth factor receptors in brain trophism and plasticity. Di Liberto V; Mudo G; Fuxe K; Belluardo N Curr Protein Pept Sci; 2014; 15(7):691-702. PubMed ID: 25175454 [TBL] [Abstract][Full Text] [Related]
91. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Tulpule A; Guan J; Neel DS; Allegakoen HR; Lin YP; Brown D; Chou YT; Heslin A; Chatterjee N; Perati S; Menon S; Nguyen TA; Debnath J; Ramirez AD; Shi X; Yang B; Feng S; Makhija S; Huang B; Bivona TG Cell; 2021 May; 184(10):2649-2664.e18. PubMed ID: 33848463 [TBL] [Abstract][Full Text] [Related]
92. Chromosomal translocations in cancer and their relevance for therapy. Taki T; Taniwaki M Curr Opin Oncol; 2006 Jan; 18(1):62-8. PubMed ID: 16357566 [TBL] [Abstract][Full Text] [Related]
93. Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study. Kim P; Jia P; Zhao Z Brief Bioinform; 2018 May; 19(3):450-460. PubMed ID: 28013235 [TBL] [Abstract][Full Text] [Related]
94. Physical and functional interactome atlas of human receptor tyrosine kinases. Salokas K; Liu X; Öhman T; Chowdhury I; Gawriyski L; Keskitalo S; Varjosalo M EMBO Rep; 2022 Jun; 23(6):e54041. PubMed ID: 35384245 [TBL] [Abstract][Full Text] [Related]
98. Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling. Paul MD; Grubb HN; Hristova K J Biol Chem; 2020 Jul; 295(29):9917-9933. PubMed ID: 32467228 [TBL] [Abstract][Full Text] [Related]
99. Feedback regulation of RTK signaling in development. Neben CL; Lo M; Jura N; Klein OD Dev Biol; 2019 Mar; 447(1):71-89. PubMed ID: 29079424 [TBL] [Abstract][Full Text] [Related]
100. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]